Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis

References

• Bradley WG. Polymyositis. Br J Hosp Med 1977;17:351–5.
   PubMedGoogle Scholar
• Cherin P. Recognition and management of myositis. Drugs 1997;54:39–49.
   PubMed Web of Science ®Google Scholar
• Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin prepara-tions. Lancet 1993;341: 789–90.
   Google Scholar
• Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human antoantibodies reactive with synthetic autoantigens from T-cell receptor /3 chain. Proc Natl Acad Sci USA 1992;89:3325–9.
   PubMed Web of Science ®Google Scholar
• Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement frag-ments. J Clin Invest 1994;94:1729–35.
   PubMed Web of Science ®Google Scholar
• Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effects of Intravenous immunoglobulins (IVIG) on peripheral blood B, NK and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71:309–14.
   PubMedGoogle Scholar
• Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and mono-cytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781–90.
   PubMed Web of Science ®Google Scholar
• Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258:513–5.
   Google Scholar
• Cherin P, Herson S, Wechsler B, Piette JC, Bletry 0, Ziza JM, et al. Intravenous immunoglobulin for polymyositis and dermat-omyositis [letter]. Lancet 1990;336:116.
   PubMedGoogle Scholar
• Cherin P, Herson S, Wechsler B, Piette JC, Bletry 0, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91: 162–8.
   Google Scholar
• Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991;91:169–72.
   Google Scholar
• Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doom PA. Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 1993;137:1979–82.
   PubMedGoogle Scholar
• Finielz P, Gendoo Z, Chuet C, Guiserix J. Dermatomyositis in a patient under chronic hemodialysis: treatment with intravenous immunoglobulins. Ann Med Interne (Paris) 1994;145:148–9.
   PubMedGoogle Scholar
• Brownell AK. Intravenous immune globulin for dermatomyositis. N Engl J Med 1994;330:1392–3.
   PubMedGoogle Scholar
• Cherin P, Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psy-chiatry 1994;57(Suppl):50–4.
   Google Scholar
• Cherin P, Piette JC, Wechsler B, Bletry 0, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in poly-myositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994;21: 1092–7.
   Google Scholar
• Vedanarayanan V, Subramony SH, Ray LI, Evans OB. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 1995;13:336–9.
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita 0, Puddu P. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 1996;15:215–6.
   Google Scholar
• Moriguchi M, Suzuki T, Tateishi M, Hara M, Kashiwazaki S. Intravenous immunoglobulin therapy for refractory myositis. Intern Med 1996;35:663–7.
   Google Scholar
• Tsai MJ, Lai CC, Lin SC, Chiang BL, Chou CC, Hsieh KH. Intravenous immunoglobulin therapy in juvenile dermatomyosi-tis. Acta Paediatr Sin 1997;38:111–5.
   Google Scholar
• Furuya Y, Takahashi T, Hamamoto H, Nishimura M, Kawakami Y. High-dose immunoglobulin therapy for a patient with der-matomyositis. Intem Med 1998;37:642–5.
   Google Scholar
• Peake MF, Perkins P, Elston DM, Older SA, Vinson RP. Cuta-neous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis 1998;62:89–93.
   Google Scholar
• Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int 1999;41:696–7.
   PubMedGoogle Scholar
• Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 1999;26:457–9.
   Google Scholar
• Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIG) in dermato-myositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000;10: 29–35.
   Google Scholar
• Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-/31 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000;94:99–104.
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermato-myositis: efficacy and safety. J Rheumatol 2000;27:2498–503.
   Google Scholar
• Hara M, Kinoshita M, Saito E, Hashimoto H, Miyasaka N, Yoshida T, et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyo-sitis and dermatomyositis. Mod Rheumatol 2003;13:319–25.
   PubMedGoogle Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344–7.
   PubMed Web of Science ®Google Scholar
• Saito E. Relationship between serum CK levels and effectiveness on polymyositis or dermatomyositis after corticosteroid therapy. Clin Rheumatol 2004;16:188–96.
   Google Scholar
• Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662–4.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurol-ogy 1994;44:223–6.
   PubMed Web of Science ®Google Scholar
• Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;26:217–8.
   Google Scholar
• Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction com-plicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257–8.
   Google Scholar
• Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773–81.
   PubMed Web of Science ®Google Scholar
• Lazarus AH, Freedman J, Semple JW. Intravenous immuno-globulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci 1998;19:289–94.
   Google Scholar
• Sussmann GL, Pruzanski W. The role of intravenous infusions of gamma globulin in the therapy of polymyositis and dermatomy-ositis. J Rheumatol 1994;21:990–2.
   PubMedGoogle Scholar
• Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974–81.
   PubMed Web of Science ®Google Scholar
• Qi M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995;38:146.
   PubMedGoogle Scholar
• Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, et al. Intravenous immunoglobulin treatment of experimental T cell mediated autoimmune disease: upregulation of T cell proliferation and downregulation of tumor necrosis factor secretion. J Clin Invest 1994;93:600–5.
   PubMed Web of Science ®Google Scholar